$SCNX
Scienture Holdings, Inc. Stock $scnx

$scnx Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000149315224025217 Filed on June 26, 2024

Income Statement

Concept	2024 Q1	2023 Q1
Revenue		$2.248M
YoY Change		-30.63%
Cost Of Revenue		$690.7K
YoY Change		-63.74%
Gross Profit		$1.557M
YoY Change		16.57%
Gross Profit Margin		69.27%
Selling, General & Admin	$5.496M	$1.904M
YoY Change	188.61%	-17.35%
% of Gross Profit		122.31%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$500.00	$2.821K
YoY Change	-82.28%	-28.94%
% of Gross Profit		0.18%
Operating Expenses	$5.496M	$1.904M
YoY Change	188.61%	-17.35%
Operating Profit	-$5.496M	-$347.4K
YoY Change	1482.15%	-64.13%
Interest Expense	$98.52K	$62.39K
YoY Change	57.9%	-4687.65%
% of Operating Profit
Other Income/Expense, Net	-$1.140M	$21.70K
YoY Change	-5356.26%	693.02%
Pretax Income	-$6.637M	-$325.7K
YoY Change	1937.68%	-66.28%
Income Tax
% Of Pretax Income
Net Earnings	$21.25M	-$678.0K
YoY Change	-3233.85%	-29.81%
Net Earnings / Revenue		-30.16%
Basic Earnings Per Share	$20.49	-$0.07
Diluted Earnings Per Share	$16.77	-$0.06
COMMON SHARES
Basic Shares Outstanding	1.205M shares	10.11M shares
Diluted Shares Outstanding	1.267M shares	670.7K shares

Balance Sheet

Concept	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$3.499M	$1.194M
YoY Change	193.01%	-36.17%
Cash & Equivalents	$3.499M	$1.200M
Short-Term Investments
Other Short-Term Assets	$174.2K	$357.9K
YoY Change	-51.31%	-13.04%
Inventory	$5.372K	$126.3K
Prepaid Expenses	$174.2K	$357.9K
Receivables	$6.937K	$707.9K
Other Receivables	$9.041M	$0.00
Total Short-Term Assets	$14.03M	$2.386M
YoY Change	487.85%	-33.67%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.000K	$62.39K
YoY Change	-88.78%	-95.02%
Goodwill
YoY Change
Intangibles	$0.00
YoY Change
Long-Term Investments	$2.500M
YoY Change
Other Assets	$22.04K	$49.03K
YoY Change	-55.05%	0.0%
Total Long-Term Assets	$2.712M	$1.652M
YoY Change	64.23%	-26.37%
TOTAL ASSETS
Total Short-Term Assets	$14.03M	$2.386M
Total Long-Term Assets	$2.712M	$1.652M
Total Assets	$16.74M	$4.038M
YoY Change	314.57%	-30.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$953.1K	$515.8K
YoY Change	84.79%	-43.23%
Accrued Expenses	$493.4K	$303.2K
YoY Change	62.72%	-41.71%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00
YoY Change		-100.0%
Total Short-Term Liabilities	$2.951M	$2.550M
YoY Change	15.73%	59.75%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$169.0K	$832.5K
YoY Change	-79.7%	-18.62%
Total Long-Term Liabilities	$169.0K	$832.5K
YoY Change	-79.7%	-38.62%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.951M	$2.550M
Total Long-Term Liabilities	$169.0K	$832.5K
Total Liabilities	$3.120M	$3.383M
YoY Change	-7.75%	13.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$24.67M	-$19.90M
YoY Change	23.97%
Common Stock	$14.00	$100.00
YoY Change	-86.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$13.62M	$655.1K
YoY Change
Total Liabilities & Shareholders Equity	$16.74M	$4.038M
YoY Change	314.57%	-30.86%

Cashflow Statement

Concept	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	$21.25M	-$678.0K
YoY Change	-3233.85%	-29.81%
Depreciation, Depletion And Amortization	$500.00	$2.821K
YoY Change	-82.28%	-28.94%
Cash From Operating Activities	-$10.19M	-$931.5K
YoY Change	993.86%	-6.92%
INVESTING ACTIVITIES
Capital Expenditures	$2.500M	$87.07K
YoY Change	2771.25%
Acquisitions
YoY Change
Other Investing Activities	$29.93M	$420.3K
YoY Change	7022.23%	1727.26%
Cash From Investing Activities	$27.43M	$333.2K
YoY Change	8133.14%	1348.68%
FINANCING ACTIVITIES
Cash Dividend Paid	$12.67M
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$13.90M	$681.3K
YoY Change	-2139.76%	-348.52%
NET CHANGE
Cash From Operating Activities	-$10.19M	-$931.5K
Cash From Investing Activities	$27.43M	$333.2K
Cash From Financing Activities	-$13.90M	$681.3K
Net Change In Cash	$3.347M	$82.92K
YoY Change	3936.16%	-106.62%
FREE CASH FLOW
Cash From Operating Activities	-$10.19M	-$931.5K
Capital Expenditures	$2.500M	$87.07K
Free Cash Flow	-$12.69M	-$1.019M
YoY Change	1145.79%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent		usd
CY2023Q4	us-gaap	Long Term Investments LongTermInvestments		usd
CY2024Q1	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent		usd
CY2024Q1	MEDS	Contingent Funding Liabilities ContingentFundingLiabilities		usd
CY2024Q1	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent		usd
CY2024Q1	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent		usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2024Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold		usd
CY2024Q1	us-gaap	Gross Profit GrossProfit		usd
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2023Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables		usd
CY2023Q1	us-gaap	Payments Of Dividends PaymentsOfDividends		usd
CY2024Q1	MEDS	Proceeds From Sale Of Future Revenue ProceedsFromSaleOfFutureRevenue		usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2023Q1	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations		usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	MEDS	Other Receivable Pursuant To Disposition OtherReceivablePursuantToDisposition		usd
CY2024Q1	MEDS	Insurance Premium Financed InsurancePremiumFinanced		usd
CY2024Q1	us-gaap	Notes Issued1 NotesIssued1		usd
CY2024Q1	MEDS	Disposition Of Related Party Assets DispositionOfRelatedPartyAssets		usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q1	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold		usd
CY2023Q1	MEDS	Disposal Group Including Discontinued Operation Gain Loss On Dispositions DisposalGroupIncludingDiscontinuedOperationGainLossOnDispositions		usd
CY2023Q1	MEDS	Disposal Group Including Discontinued Operation Other Income Expenses DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenses		usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials		usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials		usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross		usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization		usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2024Q1	MEDS	Insurance Refunds Payable InsuranceRefundsPayable		usd
CY2023Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instrument Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentOutstandingIntrinsicValue		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2024Q1	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations		shares
CY2024Q1	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeited In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2024Q1	us-gaap	Gross Profit GrossProfit		usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue		usd
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Tampa
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33634
CY2024Q1	dei	City Area Code CityAreaCode	(800)
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	261-0281
CY2024Q1	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 Par Value Per Share
CY2024Q1	dei	Trading Symbol TradingSymbol	MEDS
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1406348	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3498812	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	361	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	6937	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	5372	usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	174230	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	50724	usd
CY2024Q1	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	1300000	usd
CY2023Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	1300000	usd
CY2024Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	9041465	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	1224702	usd
CY2023Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	167816	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	14026816	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	2753063	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7500	usd
CY2024Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	22039	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	10531	usd
CY2024Q1	us-gaap	Long Term Investments LongTermInvestments	2500000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	183414	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	191216	usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	9570603	usd
CY2024Q1	us-gaap	Assets Assets	16739269	usd
CY2023Q4	us-gaap	Assets Assets	12532913	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	953098	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1497225	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	493398	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	163521	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5441	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	67831	usd
CY2023Q4	MEDS	Contingent Funding Liabilities ContingentFundingLiabilities	1246346	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	32608	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	32595	usd
CY2024Q1	MEDS	Warrant Liability WarrantLiability	1466842	usd
CY2023Q4	MEDS	Warrant Liability WarrantLiability	736953	usd
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	7811884	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2951387	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11556355	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	168976	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	176909	usd
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Noncurrent LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent	257296	usd
CY2024Q1	us-gaap	Liabilities Liabilities	3120363	usd
CY2023Q4	us-gaap	Liabilities Liabilities	11990560	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1406348	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1406348	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	905008	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	905008	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	14	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	9	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	38289871	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	33788284	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-24670979	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33245940	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	13618906	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	542353	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16739269	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12532913	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	493316	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	420097	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	73219	usd
CY2024Q1	us-gaap	Salaries And Wages SalariesAndWages	223172	usd
CY2023Q1	us-gaap	Salaries And Wages SalariesAndWages	203401	usd
CY2024Q1	us-gaap	Professional Fees ProfessionalFees	179553	usd
CY2023Q1	us-gaap	Professional Fees ProfessionalFees	135954	usd
CY2024Q1	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	339047	usd
CY2023Q1	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	248216	usd
CY2024Q1	MEDS	Technology Expense TechnologyExpense	53859	usd
CY2023Q1	MEDS	Technology Expense TechnologyExpense	43717	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4700840	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	248021	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	5496471	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	879309	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-5496471	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-806090	usd
CY2024Q1	MEDS	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	-729889	usd
CY2023Q1	MEDS	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	79891	usd
CY2024Q1	us-gaap	Interest Income Other InterestIncomeOther	62921	usd
CY2023Q1	us-gaap	Interest Income Other InterestIncomeOther	4198	usd
CY2024Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-374968	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-352244	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	98515	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	62392	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1140451	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-330547	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-6636922	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1136637	usd
CY2024Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	27882955	usd
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	458684	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	21246033	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-677953	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-6.40
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.69
CY2024Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-6.40
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.69
CY2024Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	26.89
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.68
CY2024Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	22.01
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.68
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	20.49
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.01
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	16.77
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.01
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1036756	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	670716	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1266977	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	670716	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	342867	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	63486	usd
CY2023Q1	MEDS	Disposition Of Assets Related Party DispositionOfAssetsRelatedParty	912299	usd
CY2023Q1	MEDS	Stock Issued During Period Value Warrants Exercised For Cash StockIssuedDuringPeriodValueWarrantsExercisedForCash	7	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	14434	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-677953	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	655140	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	542353	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	542353	usd
CY2024Q1	us-gaap	Dividends Dividends	12671072	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	4450919	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9840	usd
CY2024Q1	MEDS	Stock Issued During Period Value Warrants Exercised For Cash StockIssuedDuringPeriodValueWarrantsExercisedForCash	16567	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	24266	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	21246033	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	21246033	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13618906	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	13618906	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-6636922	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1136637	usd
CY2024Q1	us-gaap	Depreciation Depreciation	500	usd
CY2023Q1	us-gaap	Depreciation Depreciation	2821	usd
CY2024Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	24266	usd
CY2023Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	14434	usd
CY2024Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	4450919	usd
CY2023Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	63486	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-32074	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	7803	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	49498	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1555	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-52761	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	135013	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	22866	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4404	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6672	usd
CY2024Q1	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	7816763	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-7920	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-47359	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-544127	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-166887	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	329876	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-210844	usd
CY2024Q1	MEDS	Increase Decrease In Current Liabilities IncreaseDecreaseInCurrentLiabilities	-62390	usd
CY2023Q1	MEDS	Increase Decrease In Current Liabilities IncreaseDecreaseInCurrentLiabilities	161648	usd
CY2024Q1	MEDS	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	729889	usd
CY2023Q1	MEDS	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	-79891	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-9662731	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1358582	usd
CY2024Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-526942	usd
CY2023Q1	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	427051	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10189673	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-931531	usd
CY2024Q1	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	2500000	usd
CY2023Q1	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	87072	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-2500000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-87072	usd
CY2024Q1	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	29932589	usd
CY2023Q1	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	420269	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	27432589	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	333197	usd
CY2024Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1246346	usd
CY2023Q1	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	143750	usd
CY2024Q1	us-gaap	Payments Of Dividends PaymentsOfDividends	12671072	usd
CY2023Q1	MEDS	Proceeds From Sale Of Future Revenue ProceedsFromSaleOfFutureRevenue	825000	usd
CY2024Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	16567	usd
CY2023Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	7	usd
CY2024Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9840	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-13891011	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	681257	usd
CY2024Q1	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-5000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-13896011	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	681257	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3346905	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	82923	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	151907	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1111156	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3498812	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1194079	usd
CY2024Q1	MEDS	Other Receivable Pursuant To Disposition OtherReceivablePursuantToDisposition	7500000	usd
CY2023Q1	MEDS	Insurance Premium Financed InsurancePremiumFinanced	224055	usd
CY2023Q1	us-gaap	Notes Issued1 NotesIssued1	500000	usd
CY2023Q1	MEDS	Disposition Of Related Party Assets DispositionOfRelatedPartyAssets	492030	usd
CY2023Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	Effective June 21, 2023, the Company executed a 1:15 reverse stock split for stockholders of record on that date.
CY2023Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.00
CY2024Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	9041465	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1224702	usd
CY2024Q1	MEDS	Disposal Group Including Discontinued Operation Other Receivables DisposalGroupIncludingDiscontinuedOperationOtherReceivables	7500000	usd
CY2024Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	190242	shares
CY2024Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-6.40
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-1.69
CY2024Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-6.40
CY2023Q1	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-1.69
CY2024Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	26.89
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.68
CY2024Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	22.01
CY2023Q1	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0.68
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	20.49
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.01
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	16.77
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.01
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-24670979	usd
CY2024Q1	us-gaap	Cash Cash	3498812	usd
CY2023	MEDS	Gain Loss On Disposal Of Assets GainLossOnDisposalOfAssets	3300225	usd
CY2024Q1	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	29685946	usd
CY2024Q1	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	970808	usd
CY2023Q1	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	1754434	usd
CY2023Q1	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	270573	usd
CY2024Q1	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	970808	usd
CY2023Q1	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	1483861	usd
CY2024Q1	MEDS	Disposal Group Including Discontinued Operation Wages And Salary Expense DisposalGroupIncludingDiscontinuedOperationWagesAndSalaryExpense	551983	usd
CY2023Q1	MEDS	Disposal Group Including Discontinued Operation Wages And Salary Expense DisposalGroupIncludingDiscontinuedOperationWagesAndSalaryExpense	702498	usd
CY2024Q1	MEDS	Disposal Group Including Discontinued Operation Professional Expense DisposalGroupIncludingDiscontinuedOperationProfessionalExpense	15385	usd
CY2023Q1	MEDS	Disposal Group Including Discontinued Operation Professional Expense DisposalGroupIncludingDiscontinuedOperationProfessionalExpense	3707	usd
CY2024Q1	MEDS	Disposal Group Including Discontinued Operation Technology Expense DisposalGroupIncludingDiscontinuedOperationTechnologyExpense	86660	usd
CY2023Q1	MEDS	Disposal Group Including Discontinued Operation Technology Expense DisposalGroupIncludingDiscontinuedOperationTechnologyExpense	189568	usd
CY2024Q1	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	36029	usd
CY2023Q1	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	129404	usd
CY2024Q1	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	690057	usd
CY2023Q1	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	1025177	usd
CY2024Q1	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	280751	usd
CY2023Q1	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	458684	usd
CY2024Q1	MEDS	Disposal Group Including Discontinued Operation Gain Loss On Dispositions DisposalGroupIncludingDiscontinuedOperationGainLossOnDispositions	27602204	usd
CY2024Q1	MEDS	Disposal Group Including Discontinued Operation Other Income Expenses DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenses	27602204	usd
CY2024Q1	MEDS	Disposal Group Including Discontinued Operation Other Income Loss From Discontinued Opeations DisposalGroupIncludingDiscontinuedOperationOtherIncomeLossFromDiscontinuedOpeations	27882955	usd
CY2023Q1	MEDS	Disposal Group Including Discontinued Operation Other Income Loss From Discontinued Opeations DisposalGroupIncludingDiscontinuedOperationOtherIncomeLossFromDiscontinuedOpeations	458684	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	493316	usd
CY2023Q1	us-gaap	Assets Assets	4037771	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-677953	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	690670	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5372	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	968	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	5372	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	968	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	9777478	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	814790	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8962688	usd
CY2024Q1	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P5Y
CY2023Q4	MEDS	Insurance Refunds Payable InsuranceRefundsPayable	62390	usd
CY2024Q1	MEDS	Other Payables OtherPayables	5441	usd
CY2023Q4	MEDS	Other Payables OtherPayables	5441	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	5441	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	67831	usd
CY2023Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	Effective June 21, 2023, the Company executed a 1:15 reverse stock split for stockholders of record on that date.
CY2023Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	4450919	usd
CY2024Q1	MEDS	Cash Dividend CashDividend	8.00
CY2024Q2	MEDS	Special Cash Dividend SpecialCashDividend	12671072	usd
CY2024Q1	MEDS	Warrant Liability WarrantLiability	1466842	usd
CY2024Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	729899	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	218729	shares
CY2023Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	19.62
CY2023	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm	P3Y11M12D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	28487	shares
CY2024Q1	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice	7.14
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	190242	shares
CY2024Q1	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	21.48
CY2024Q1	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm	P3Y6M29D
CY2024Q1	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instrument Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentOutstandingIntrinsicValue	130109	usd
CY2024Q1	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisable	190242	shares
CY2024Q1	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisableWeightedAverageExercisePrice	21.48
CY2024Q1	MEDS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityExercisableWeightedAverageRemainingContractualTerm1	P3Y6M29D
CY2024Q1	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instrument Exercisable Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentExercisableIntrinsicValue	130109	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	24266	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	14434	usd
CY2024Q1	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p id="xdx_80C_eus-gaap--LossContingencyDisclosures_znYobOYUvSGc" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 16 – <span id="xdx_82F_zPlfsd8huNv9">CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Studebaker Defense Group, LLC</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2020, the Company’s wholly-owned subsidiary, IPS, entered into an agreement with Studebaker Defense Group, LLC (“Studebaker”) wherein IPS would pay Studebaker a down payment of $<span id="xdx_90B_ecustom--DownPayment_c20200701__20200731__dei--LegalEntityAxis__custom--IPSMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember_zN3LOf7FLcM4" title="Down payment">550,000</span> and Studebaker would deliver <span id="xdx_90A_ecustom--NumberOfNitrileGlovesDelivered_uInteger_c20200813__20200814__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember__dei--LegalEntityAxis__custom--IPSMember_z6CUe9uqzdoe" title="Number of nitrile gloves delivered">180,000</span> boxes of nitrile gloves by August 14, 2020. IPS wired the $<span id="xdx_90E_eus-gaap--LossContingencyDamagesSoughtValue_c20200701__20200731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember__dei--LegalEntityAxis__custom--IPSMember_z1R6oIelss65" title="Loss contingency damages sought value">550,000</span> to Studebaker, but to date, Studebaker has not delivered the gloves or provided a refund of the deposit. In December 2020, the Company filed a complaint against Studebaker in Florida state court, Case No. 20-CA-010118 in the Circuit Court for the Thirteenth Judicial Circuit in Hillsborough County, for among other things, breach of contract. Studebaker did not answer the complaint, nor did counsel for Studebaker file an appearance. Accordingly, in February 2021, the Company filed for a default judgment; however, on March 22, 2021, counsel for Studebaker filed an appearance and shortly thereafter filed a motion to vacate the default judgment and dismiss the complaint on jurisdictional grounds. The court granted Studebaker’s motion to set aside the default judgment but denied the motion to dismiss. At June 30, 2021, the $<span id="xdx_907_ecustom--LossOnInventoryInvestment_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember__dei--LegalEntityAxis__custom--IPSMember_zx358bKBRJ37" title="Loss on inventory investment">500,000</span> was recorded as Loss on Inventory Investment. The Company won this case but has not collected any settlement yet, another lawsuit was filed to collect.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 13, 2023, a settlement was reached in the Studebaker and IPS legal case. The court found in favor of IPS and ordered Studebaker to pay $<span id="xdx_90B_eus-gaap--RepaymentsOfRelatedPartyDebt_c20230412__20230413_zNwsDmwQL6j4" title="Repayments of related party debt">550,000</span> to IPS. The payments were to commence on May 1, 2023 and continue monthly in 17 installments until the full amount is paid in full but as of the filing date, no payment has been received by IPS.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>GSG PPE, LLC</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 19, 2021, IPS filed a complaint against GSG PPE, LLC (“GSG”) and Gary Waxman (“Waxman”), the owner, alleging three counts of breach of contract for a purchase agreement, a promissory note, and a personal guaranty. Collectively, the company alleges that GSG and Waxman have materially breached all three contracts. In late 2020, GSG and IPS executed a valid initial contract setting the terms of a business transaction. GSG failed to pay IPS approximately 75% of the amount owed to IPS. GSG acknowledged it owed the money and executed a promissory note in favor of IPS in the amount of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20210930_zEL3sdoTDTRl" title="Principal amount">630,000</span> which matured on September 30, 2021. The note provides for attorney fees and interest in addition to the $<span id="xdx_907_ecustom--AttorneyFees_c20240101__20240331_zXlbL7zSmX0l" title="Attorney fees">630,000</span>. Waxman’s personal guaranty confirmed that GSG owed IPS $<span id="xdx_90A_eus-gaap--DebtInstrumentFaceAmount_iI_c20240331__srt--TitleOfIndividualAxis__custom--WaxmanMember_zfTGZyKNBCt3" title="Principal amount">630,000</span>. On September 30, 2021, the $<span id="xdx_909_eus-gaap--ProvisionForDoubtfulAccounts_c20210928__20210930_zXDQhwVw86y3" title="Bad debt expenses">630,000</span> was recorded as Bad Debt Expense. A settlement was entered into between the parties in June 2022, whereby GSG and Waxman agreed to pay $<span id="xdx_903_eus-gaap--LegalFees_c20220601__20220630_zSSoJViCsSJ" title="Attorney fees">743,000</span> which included attorney fees and interest, which is required to be paid to the Company in monthly installments over 17 months. The Company received additional monthly installment payments as part of the agreement through January 2023. As of March 31, 2024, and through the date of this filing, the Company has not received the monthly installment payments due to the Company from GSG since January of 2023. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"> </p>
CY2023Q2	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	550000	usd
CY2021Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	630000	usd
CY2024Q1	MEDS	Attorney Fees AttorneyFees	630000	usd
CY2021Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	630000	usd
CY2022Q2	us-gaap	Legal Fees LegalFees	743000	usd
CY2022Q1	MEDS	Increase In Right Of Use Asset IncreaseInRightOfUseAsset	977220	usd
CY2022Q1	us-gaap	Security Deposit SecurityDeposit	38500	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	642887	usd
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	664992	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	313301	usd
CY2023Q4	MEDS	Operating Lease Liability Right Of Use Assets OperatingLeaseLiabilityRightOfUseAssets	351581	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	39132	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	53652	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	55261	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	56919	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	48612	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	253576	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	51992	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	201584	usd
CY2024Q1	MEDS	Lease Obligation Current LeaseObligationCurrent	32608	usd
CY2024Q1	MEDS	Operating Lease Liabilities Noncurrent OperatingLeaseLiabilitiesNoncurrent	168976	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10	pure
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y6M18D
CY2024Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	20925	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	81024	usd
CY2024Q1	MEDS	Operating Lease Expense Including Discontinued Operations OperatingLeaseExpenseIncludingDiscontinuedOperations	62656	usd
CY2023Q1	MEDS	Operating Lease Expense Including Discontinued Operations OperatingLeaseExpenseIncludingDiscontinuedOperations	62656	usd
CY2024Q1	us-gaap	Assets Assets	16739269	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	21246033	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	493316	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	73219	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
meds-20240331_pre.xml	Edgar Link	unprocessable
meds-20240331_def.xml	Edgar Link	unprocessable
0001493152-24-025217-index-headers.html	Edgar Link	pending
0001493152-24-025217-index.html	Edgar Link	pending
0001493152-24-025217.txt	Edgar Link	pending
0001493152-24-025217-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
form10-q_001.jpg	Edgar Link	pending
meds-20240331.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
meds-20240331_cal.xml	Edgar Link	unprocessable
meds-20240331_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SCNX
Scienture Holdings, Inc. Stock $scnx

2024 Q1 Form 10-Q Financial Statement

#000149315224025217 Filed on June 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SCNX Scienture Holdings, Inc. Stock $scnx

2024 Q1 Form 10-Q Financial Statement

#000149315224025217 Filed on June 26, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SCNX
Scienture Holdings, Inc. Stock $scnx